A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints
Titel:
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints
Auteur:
Ferry, D. R. Deakin, M. Baddeley, J. Daryanani, S. Bramhall, S. Anderson, D. A. Wakelam, M. J. O. Doran, J. Pemberton, G. Young, A. M. Buckels, J. Kerr, D. J.